CTOs on the Move

Indevus Pharmaceuticals

www.indevus.com

 
Indevus Pharmaceuticals Inc. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.indevus.com
  • 33 Hayden Ave
    Lexington, MA USA 02421
  • Phone: 781.861.8444

Executives

Name Title Contact Details

Similar Companies

Allied Biotech

Allied Biotech is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Sciences

Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acureon Pharmaceuticals

Acureon Pharmaceuticals is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Allucent

Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive operational expertise. Allucent is dedicated to helping clients navigate the complexities of drug development and regulatory approval, ultimately accelerating the delivery of breakthrough therapies to patients.